CIK 0001651308 · Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981209416
- Phone
- 41-616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-08 | OYLER JOHN Chief Executive Officer | Sale | −1,120 | $271.14 | $304K | 0 |
| 2026-06-01 | Yi Qingqing Director | Sale | −235 | $279.13 | $66K | 0 |
| 2026-05-22 | Dugan Margaret Director | Sale | −212 | $309.60 | $66K | 0 |
| 2026-05-22 | Riva Alessandro Director | Sale | −212 | $309.51 | $66K | 0 |
| 2026-05-22 | Sanders Corazon (Corsee) D. Director | Sale | −212 | $309.59 | $66K | 0 |
| 2026-05-22 | BAKER BROS. ADVISORS LP Director | Sale | −2,743 | $23.85 | $65K | 145,322 |
| 2026-05-22 | BAKER BROS. ADVISORS LP Director | Sale | −2,743 | $23.85 | $65K | 145,326 |
| 2026-05-22 | BAKER BROS. ADVISORS LP Director | Sale | −2,756 | $23.79 | $66K | 142,566 |
| 2026-05-22 | BAKER BROS. ADVISORS LP Director | Sale | −2,756 | $23.79 | $66K | 142,570 |
| 2026-05-13 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +101 | $194.47 | $20K | 101 |
| 2026-05-13 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +133 | $213.32 | $28K | 234 |
| 2026-05-13 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +98 | $159.03 | $16K | 332 |
| 2026-05-13 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −332 | $310.72 | $103K | 0 |
| 2026-05-13 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −1,313 | 19,864 | ||
| 2026-05-13 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −1,729 | 83,226 | ||
| 2026-05-13 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −1,274 | 107,848 | ||
| 2026-04-08 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +101 | $194.47 | $20K | 101 |
| 2026-04-08 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +133 | $213.32 | $28K | 234 |
| 2026-04-08 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +98 | $159.03 | $16K | 332 |
| 2026-04-08 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −332 | $311.59 | $103K | 0 |
Page 13 of 71 · 1,406 trades